In 2007, OHSU’s Markus Grompe, M.D., and collaborators, developed an animal model for studying a human-specific parasite that causes malaria. Just recently, this mouse model was used by investigators at Seattle Biomedical Research Institute to gain a better understanding of how proteins are expressed in the liver during infection. Their research was published online in the Journal of Clinical Investigation.
The technology was licensed to Yecuris Corporation back in 2007, a biotech company founded by Dr. Grompe.
Yecuris president and CEO John Bial said of this new breakthrough: “The extensive collaborative relationships and risk-taking involved in planning and executing this research is a testament to the tireless dedication of these teams to solving one of the globe’s oldest killers. It also highlights how private and public funding can come together effectively to address critical challenges in global health.”
Read the full OHSU News release for more.
The OHSU research leading to the development of the FRGTM KO mouse was funded by the National Institutes of Health and the The Oregon Opportunity fund.